0,1,2,3,4,5
"Table 6.3.8:  Oncological results of selected salvage cryoablation of the prostate case series, including at",,,,,
Study,n,"Median 
FU (mo)","Time point 
of outcome 
measurement 
(yr)",BCR-free probability,Definition of failure
"Ginsburg, et al. 2017 [1084]",898,19.0,5,71.3%,Phoenix criteria
"Spiess, et al. 2010 [1085]",450,40.8,3.4,39.6%,PSA > 0.5 ng/mL
"Li, et al. 2015 [1086]",486,18.2,5,63.8%,Phoenix criteria
"Kovac, et al. 2016 [1087]",486,18.2,5,"75.5%  
(nadir PSA < 0.4 ng/mL);
22.1%  
(nadir PSA > 0.4 ng/mL)",Phoenix criteria
"Ahmad, et al. 2013 [1088]",283,23.9,3,"67.0%  
(nadir PSA < 1 ng/mL);
14.0%  
(nadir PSA > 1 ng/mL)",Phoenix criteria
"Pisters, et al. 2008 [1089]",279,21.6,5,"58.9% (ASTRO)
54.5% (Phoenix)","ASTRO and Phoenix 
criteria"
